Discontinuation report RIFADIN
| Report ID | 134218 |
| Drug Identification Number | 02092808 |
| Brand name | RIFADIN |
| Common or Proper name | Rifampin capsule |
| Company Name | SANOFI-AVENTIS CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | RIFAMPIN |
| Strength(s) | 300MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 100 |
| ATC code | J04AB |
| ATC description | DRUGS FOR TREATMENT OF TUBERCULOSIS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2021-01-28 |
| Remaining supply date | 2021-01-28 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2021-02-16 | French | Compare |
| v1 | 2021-02-16 | English | Compare |
Showing 1 to 2 of 2